Literature DB >> 17123047

[Soft tissue carcinoma. Epidemiology, diagnostics and therapy].

H Rechl1, K Wörtler, G Weirich, K Specht, R Gradinger.   

Abstract

The treatment of soft tissue sarcoma requires an individually tailored, multimodal therapy due to the high variability in the clinical situation. Resection is the usual treatment for patients with superficial, low grade tumors with a diameter of <5 cm. For intermediate grade, differentiated lesions, resection with negative resection edges combined with radiotherapy attains an almost 80% total survival rate. For patients with high grade sarcoma of >5 cm, local control can be attained by resection and radiotherapy, however every second patient will develop metastases. Patients with a local recurrence should consider a new resection. Radiotherapy is the more effective the lower the remaining postoperative tumor burden.

Entities:  

Mesh:

Year:  2006        PMID: 17123047     DOI: 10.1007/s00132-006-1032-9

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  9 in total

1.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.

Authors:  P W Pisters; D H Leung; J Woodruff; W Shi; M F Brennan
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

2.  Comparison between the in vitro intrinsic radiation sensitivity of human soft tissue sarcoma and breast cancer cell lines.

Authors:  W Ruka; A Taghian; D Gioioso; J A Fletcher; F Preffer; H D Suit
Journal:  J Surg Oncol       Date:  1996-04       Impact factor: 3.454

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  Patterns of recurrence in patients with high-grade soft-tissue sarcomas.

Authors:  D A Potter; J Glenn; T Kinsella; E Glatstein; E E Lack; C Restrepo; D E White; C A Seipp; R Wesley; S A Rosenberg
Journal:  J Clin Oncol       Date:  1985-03       Impact factor: 44.544

5.  The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.

Authors:  S A Rosenberg; J Tepper; E Glatstein; J Costa; A Baker; M Brennan; E V DeMoss; C Seipp; W F Sindelar; P Sugarbaker; R Wesley
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

6.  Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues.

Authors:  C Sadoski; H D Suit; A Rosenberg; H Mankin; J Efird
Journal:  J Surg Oncol       Date:  1993-04       Impact factor: 3.454

7.  Radiation therapy alone for sarcoma of soft tissue.

Authors:  J E Tepper; H D Suit
Journal:  Cancer       Date:  1985-08-01       Impact factor: 6.860

8.  Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons.

Authors:  W Lawrence; W L Donegan; N Natarajan; C Mettlin; R Beart; D Winchester
Journal:  Ann Surg       Date:  1987-04       Impact factor: 12.969

9.  Prognosis for soft-tissue sarcoma in the locomotor system. A retrospective population-based follow-up study of 237 patients.

Authors:  A Rydholm; N O Berg; B Gullberg; B M Persson; K G Thorngren
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1984-09
  9 in total
  3 in total

1.  [Soft tissue sarcoma. Resection and plastic reconstruction].

Authors:  H U Steinau; L Steinsträsser; J Hauser; D Tilkorn; I Stricker; A Daigeler
Journal:  Orthopade       Date:  2012-02       Impact factor: 1.087

Review 2.  [Diagnosis of malignant bone and soft tissue tumors].

Authors:  H Rechl; C Kirchhoff; K Wörtler; U Lenze; A Töpfer; R von Eisenhart-Rothe
Journal:  Orthopade       Date:  2011-10       Impact factor: 1.087

3.  [Soft tissue sarcoma : resection and plastic reconstruction].

Authors:  H U Steinau; L Steinsträsser; J Hauser; D Tilkorn; I Stricker; A Daigeler
Journal:  Chirurg       Date:  2012-07       Impact factor: 0.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.